NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

538.25 -15.55 (-2.81%)

30.40% Fall from 52W High

1.2M NSE+BSE Volume

NSE 30 Sep, 2025 3:31 PM (IST)

23,494.6

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

23 May 2017

538.25

-2.81%

Emami Ltd Q4FY17 results comment

Results Update: Emami Ltd.

HDFC Securities

Revenue decreased by 20.35% to Rs. 577.58 Cr in Q4FY17 when compared to the previous quarter.

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

09 May 2017

538.25

-2.81%

Emami (Resuming Coverage): Better days ahead. BUY

Buy: Emami Ltd.

HDFC Securities

Emami is one of the leading and fastest-growing personal and healthcare companies in India. It boasts of an enviable portfolio of household brands such as Boroplus, Navratna, Fair and Handsome, Zandu and Mentho Plus Balm, Kesh King, Sona Chandi and Zandu Chyawanprash and Fast Relief.

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

08 May 2017

538.25

-2.81%

Emami - 4QFY17 Result Update

Buy: Emami Ltd.

Reliance Securities

Emami has reported below par numbers for the quarter ended March 2017 with consolidated sales of Rs5.8bn (down 4% YoY) and net profit of Rs833mn (up 1.5% YoY). Although domestic revenues grew by 3% YoY, revenues of international business division declined by 38% YoY during the quarter. We expect Emami to report consolidated revenue and earnings CAGR of 14.7% and 18.6% respectively through FY17-19E. Considering Emami's strong brands coupled with market leadership and pricing power, we maintain our BUY recommendation on the stock with Target Price of Rs1,244 (from Rs1,211 earlier). Stagnant Growth in Domestic Business...

Emami Ltd. has lost -28.39% in the last 1 Year

Emami Ltd.

04 Feb 2017

538.25

-2.81%

Emami Ltd Q3FY17 results comment

Results Update: Emami Ltd.

HDFC Securities

Revenue grew by 24.26% to Rs. 725.17 Cr in Q3FY17 when compared to the previous quarter. Also, it rose by 0.19% when compared with Q3FY16.

Emami Ltd. is trading below all available SMAs

Emami Ltd.

03 Feb 2017

538.25

-2.81%

EARNING UPDATE - EMAMI

Buy: Emami Ltd.

Chola Wealth Direct

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales and PAT have grown at a CAGR of 18.4% and 23.2% respectively (FY08-13). Geographical breakup of sales: North (29%), West (27%), South (23%) and East (21%). Export contributes ~10.4% of total revenue. Company...

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

29 Oct 2016, 12:00AM

538.25

-2.81%

EARNING UPDATE - EMAMI

Neutral: Emami Ltd.

Chola Wealth Direct

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

28 Oct 2016

538.25

-2.81%

Emami - 2QFY17 Result Update

Buy: Emami Ltd.

Reliance Securities

Emami has posted 10.2% yoy growth in consolidated sales to Rs5.8bn in 2QFY17. While its EBITDA grew 15.3% yoy to Rs1.7bn, reported PAT rose by 9.2% yoy to Rs661mn. Volume grew by robust 10% yoy which is impressive considering current market scenario marked with weaker demand. Volume growth excluding Kesh King stood at 6% in 2Q. Expecting 17.5% revenue and 19.4% earnings CAGR through FY16-18E, we maintain our BUY recommendation on the stock with an upwardly...

Emami Ltd. is trading below all available SMAs

Is Emami Ltd. worth buying?

225 Votes:

Buy 74.67%

Sell 17.33%

Hold 8.0%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf